AI Stocks Under $3
Discover investment opportunities in AI Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
AI is analyzing your request
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under $3 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in AI Stocks Under $3 using our Smart AI Filter.
7 stocks found for "AI Stocks Under $3"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
---|---|---|---|---|---|---|
0.79 | ±100.0% | -28.5 | 0.00% | |||
0.98 | ±100.0% | -0.4 | 0.00% | |||
0.95 | ±100.0% | -495.0 | 0.00% | |||
2.04 | ±100.0% | -47.1 | 0.00% | |||
1.22 | ±88.8% | -4.8 | 0.00% | |||
1.55 | ±100.0% | -7.7 | 0.00% | |||
0.68 | ±100.0% | -38.7 | 0.00% |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
C3.ai AI and Veritone VERI are two small-cap companies at the forefront of enterprise artificial intelligence software. C3.ai, founded by tech veteran Tom Siebel, brands itself as an Enterprise AI application software provider serving industries from energy to defense.
Read moreQ: What are the growth prospects for Veritone Inc. (VERI) in the AI sector?
A: Veritone Inc. focuses on AI-driven solutions, particularly in media and legal fields. Growth prospects hinge on broader AI adoption and increased demand for cognitive engines in content curation and legal eDiscovery. Investors should monitor technological advances and industry partnerships.
Q: How does Remark Holdings Inc. (MARK) fit into the AI and digital media landscape?
A: Remark Holdings Inc. operates in AI-powered analytics, mainly focusing on facial recognition and related sectors. Its competitive advantage lies in proprietary AI tech and robust client base in retail analytics, enhancing its digital media offerings.
Q: What are the key revenue sources for Inuvo Inc. (INUV) as an AI advertising firm?
A: Inuvo Inc. generates revenue through its AI-based advertising platform, IntentKey, which enhances ad targeting accuracy. It leverages proprietary algorithms to identify intent signals, optimizing customer acquisition strategies for advertisers.
Q: Does Predictive Oncology Inc. (POAI) offer unique AI capabilities in healthcare?
A: Predictive Oncology Inc. utilizes AI in personalized oncology solutions, focusing on drug discovery. Its Helomics division leverages AI-driven tumor profiling for precision medicine, offering a unique positioning in the healthcare AI space.
Q: Are there environmental risks associated with investing in Duos Technologies Group, Inc. (DUOT)?
A: Duos Technologies specializes in intelligent automation systems. Environmental risks may stem from regulatory shifts affecting industrial automation sectors they serve. Investors should consider the company's exposure to regulated industries.
Q: How might Lantern Pharma Inc. (LTRN) leverage AI in biotechnology?
A: Lantern Pharma Inc. uses AI to accelerate drug discovery and development in oncology. By employing machine learning models, Lantern aims to reduce costs and improve success rates, holding potential for disrupting traditional pharmaceutical approaches.